CN105130998B - 库潘尼西的制备方法 - Google Patents

库潘尼西的制备方法 Download PDF

Info

Publication number
CN105130998B
CN105130998B CN201510618067.6A CN201510618067A CN105130998B CN 105130998 B CN105130998 B CN 105130998B CN 201510618067 A CN201510618067 A CN 201510618067A CN 105130998 B CN105130998 B CN 105130998B
Authority
CN
China
Prior art keywords
pannixi
preparation
propoxyl group
reaction
bases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201510618067.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN105130998A (zh
Inventor
许学农
王喆
包志坚
张文件
苏健
顾新禹
薛佳
袁玉环
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SUZHOU LIXIN PHARMACEUTICAL Co.,Ltd.
Original Assignee
SUZHOU LIXIN PHARMACY CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SUZHOU LIXIN PHARMACY CO Ltd filed Critical SUZHOU LIXIN PHARMACY CO Ltd
Priority to CN201510618067.6A priority Critical patent/CN105130998B/zh
Publication of CN105130998A publication Critical patent/CN105130998A/zh
Priority to KR1020187011225A priority patent/KR102104957B1/ko
Priority to PCT/CN2016/088091 priority patent/WO2017049983A1/zh
Application granted granted Critical
Publication of CN105130998B publication Critical patent/CN105130998B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
CN201510618067.6A 2015-09-25 2015-09-25 库潘尼西的制备方法 Active CN105130998B (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN201510618067.6A CN105130998B (zh) 2015-09-25 2015-09-25 库潘尼西的制备方法
KR1020187011225A KR102104957B1 (ko) 2015-09-25 2016-07-01 코판리십의 제조방법
PCT/CN2016/088091 WO2017049983A1 (zh) 2015-09-25 2016-07-01 库潘尼西的制备方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510618067.6A CN105130998B (zh) 2015-09-25 2015-09-25 库潘尼西的制备方法

Publications (2)

Publication Number Publication Date
CN105130998A CN105130998A (zh) 2015-12-09
CN105130998B true CN105130998B (zh) 2017-07-28

Family

ID=54716625

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510618067.6A Active CN105130998B (zh) 2015-09-25 2015-09-25 库潘尼西的制备方法

Country Status (3)

Country Link
KR (1) KR102104957B1 (und)
CN (1) CN105130998B (und)
WO (1) WO2017049983A1 (und)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105130998B (zh) * 2015-09-25 2017-07-28 苏州立新制药有限公司 库潘尼西的制备方法
KR20180101603A (ko) * 2016-02-01 2018-09-12 바이엘 파마 악티엔게젤샤프트 코판리십 바이오마커

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0326307B1 (en) * 1988-01-23 1994-08-17 Kyowa Hakko Kogyo Co., Ltd. Novel pyridazinone derivatives and pharmaceutical preparations containing them
JP2003252875A (ja) * 2002-03-04 2003-09-10 Lotte Co Ltd 新規プリン誘導体
ES2367141T3 (es) * 2002-09-30 2011-10-28 Bayer Pharma Aktiengesellschaft Derivados de azol-pirimidina condensados.
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
JP5210558B2 (ja) * 2007-07-12 2013-06-12 株式会社ブリヂストン 防振装置
EP3018131A1 (en) * 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
CN105130997B (zh) * 2015-09-25 2017-12-05 苏州明锐医药科技有限公司 一种库潘尼西的制备方法
CN105130998B (zh) * 2015-09-25 2017-07-28 苏州立新制药有限公司 库潘尼西的制备方法

Also Published As

Publication number Publication date
KR20180096572A (ko) 2018-08-29
KR102104957B1 (ko) 2020-04-28
CN105130998A (zh) 2015-12-09
WO2017049983A1 (zh) 2017-03-30

Similar Documents

Publication Publication Date Title
ES2432647T3 (es) Procedimiento para la preparación de telmisartán
CN105916861A (zh) 可用于合成软海绵素b类似物的方法
CN106966947B (zh) 一种维格列汀的制备方法
CN106366072B (zh) 一种azd9291的制备方法
JP6681922B2 (ja) イブルチニブの製造方法
CN103342704B (zh) 一种抗血栓药物阿哌沙班的制备方法
CN109912624A (zh) 一种巴洛沙韦酯关键母核中间体的合成方法
CN104098553B (zh) 替格瑞洛的中间体及其制备方法和替格瑞洛的制备方法
CN105130998B (zh) 库潘尼西的制备方法
CN104774194B (zh) 氘代的丙型肝炎病毒抑制剂
CN106749259A (zh) 一种环戊基嘧啶并吡咯类化合物的合成方法
CN105566215A (zh) 一种瑞戈非尼的制备方法
CN103923080A (zh) 一种制备抗血栓药物阿哌沙班的方法
CN105358529B (zh) 一种合成阿哌沙班重要中间体的新方法
CN107814804A (zh) 依鲁替尼的制备方法
CN105130997B (zh) 一种库潘尼西的制备方法
CN104030958B (zh) 一种（s）-1-（2-氯乙酰基）吡咯烷-2-甲腈的合成方法
CN110143951A (zh) 一种盐酸帕唑帕尼原料药三聚体杂质的合成方法
CN104725292A (zh) 一种(s)(-)-氨磺必利的制备方法
CN109020977B (zh) 一种Acalabrutinib的制备方法
CN101602707A (zh) 一类萘内酰胺衍生物及其在肿瘤细胞增殖抑制上的应用
EP3257851A1 (en) Salt form and crystal form of 1,2,5 thiadiazolidin-1,1-dioxide, preparation method thereof and intermediate
CN107722007A (zh) 阿哌沙班杂质的制备方法
CA2207464A1 (en) Crystal of n-{(quinolin-2-yl)phenylsulfonamides and process for producing the same
CN105348195A (zh) 一种美普他酚杂质d的制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20200714

Address after: Hu Suzhou high tech Zone of Jiangsu province 215151 City Road No. 21 Tang Guan District

Patentee after: SUZHOU LIXIN PHARMACEUTICAL Co.,Ltd.

Address before: 215151 No. 21 West Tong Road, hi tech Development Zone, Jiangsu, Suzhou

Co-patentee before: Xu Xuenong

Patentee before: SUZHOU LIXIN PHARMACEUTICAL Co.,Ltd.